195 related articles for article (PubMed ID: 32449226)
21. Checkpoint immunotherapy of cutaneous squamous cell carcinoma in patients suffering from chronic lymphocytic leukaemia: divergent outcomes in two men treated with PD-1 inhibitors.
Jansen P; Lodde GC; Wetter A; Welt A; Stuschke M; Dührsen U; Stoffels I; Klode J; Livingstone E; Zimmer L; Roesch A; Hadaschik E; Griewank KG; Schadendorf D; Ugurel S
J Eur Acad Dermatol Venereol; 2022 Jan; 36 Suppl 1():41-44. PubMed ID: 34855243
[TBL] [Abstract][Full Text] [Related]
22. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
Venkatesh S; Al-Haseni A; Sahni D
BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
[TBL] [Abstract][Full Text] [Related]
23. Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non-Small-cell Lung Cancer.
Okuma Y; Wakui H; Utsumi H; Sagawa Y; Hosomi Y; Kuwano K; Homma S
Clin Lung Cancer; 2018 Sep; 19(5):410-417.e1. PubMed ID: 29859759
[TBL] [Abstract][Full Text] [Related]
24. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
[TBL] [Abstract][Full Text] [Related]
25. Programmed death-1 ligands 1 and 2 expression in cutaneous squamous cell carcinoma and their relationship with tumour- infiltrating dendritic cells.
Jiao Q; Liu C; Li W; Li W; Fang F; Qian Q; Zhang X
Clin Exp Immunol; 2017 Jun; 188(3):420-429. PubMed ID: 28052400
[TBL] [Abstract][Full Text] [Related]
26. Anti-PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature.
Sellah D; Saint-Jean M; Peuvrel L; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e159-e161. PubMed ID: 30451326
[No Abstract] [Full Text] [Related]
27. T-box transcription factor 2 mediates antitumor immune response in cutaneous squamous cell carcinoma by regulating the expression of programmed death ligand 1.
Wang X; Li Z; Sun Y
Skin Res Technol; 2023 Jan; 29(1):e13254. PubMed ID: 36478592
[TBL] [Abstract][Full Text] [Related]
28. Expression of PD-L1 in keratoacanthoma and different stages of progression in cutaneous squamous cell carcinoma.
Gambichler T; Gnielka M; Rüddel I; Stockfleth E; Stücker M; Schmitz L
Cancer Immunol Immunother; 2017 Sep; 66(9):1199-1204. PubMed ID: 28501937
[TBL] [Abstract][Full Text] [Related]
29. Two cases of advanced cutaneous squamous cell carcinoma lesions on the head and neck successfully treated with nivolumab.
Ishiguro A; Ogata D; Namikawa K; Takahashi A; Yamazaki N
J Dermatol; 2021 Sep; 48(9):e434-e435. PubMed ID: 34018639
[No Abstract] [Full Text] [Related]
30. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study.
Salzmann M; Leiter U; Loquai C; Zimmer L; Ugurel S; Gutzmer R; Thoms KM; Enk AH; Hassel JC
Eur J Cancer; 2020 Oct; 138():125-132. PubMed ID: 32882466
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic implications of PD-L1 expression in bladder cancer with squamous differentiation.
Morsch R; Rose M; Maurer A; Cassataro MA; Braunschweig T; Knüchel R; Vögeli TA; Ecke T; Eckstein M; Weyerer V; Esposito I; Ackermann M; Niegisch G; Gaisa NT;
BMC Cancer; 2020 Mar; 20(1):230. PubMed ID: 32188412
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of short-term nivolumab treatment in a Chinese patient with relapsed advanced-stage lung squamous cell carcinoma: A case report.
Pi G; He H; Bi J; Li Y; Li Y; Zhang Y; Wang M; Han G; Lin C
Medicine (Baltimore); 2016 Oct; 95(40):e5077. PubMed ID: 27749580
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer.
Inoue Y; Yoshimura K; Nishimoto K; Inui N; Karayama M; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Asada K; Uto T; Fujii M; Matsui T; Matsuura S; Hashimoto D; Toyoshima M; Kusagaya H; Matsuda H; Inami N; Kaida Y; Niwa M; Ito Y; Sugimura H; Suda T
JAMA Netw Open; 2020 Sep; 3(9):e2011818. PubMed ID: 32955570
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of a programmed death-1 checkpoint inhibitor in a case of cutaneous squamous cell carcinoma harboring mutations of TP53 and BRCA2.
Ma WL; Chou CH; Chen JP; Kuo SH
Dermatol Ther; 2020 Nov; 33(6):e14035. PubMed ID: 32683791
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics of cutaneous squamous cell carcinoma: perspective for treatment strategies.
Di Nardo L; Pellegrini C; Di Stefani A; Del Regno L; Sollena P; Piccerillo A; Longo C; Garbe C; Fargnoli MC; Peris K
J Eur Acad Dermatol Venereol; 2020 May; 34(5):932-941. PubMed ID: 31747091
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of PD-1-based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma.
Kreft S; Gesierich A; Eigentler T; Franklin C; Valpione S; Ugurel S; Utikal J; Haferkamp S; Blank C; Larkin J; Garbe C; Schadendorf D; Lorigan P; Schilling B
Eur J Cancer; 2019 Jul; 116():207-215. PubMed ID: 31212163
[TBL] [Abstract][Full Text] [Related]
37. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
38. Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient.
Vidovic D; Simms GA; Pasternak S; Walsh M; Peltekian K; Stein J; Helyer LK; Giacomantonio CA
Front Immunol; 2021; 12():678028. PubMed ID: 34122442
[TBL] [Abstract][Full Text] [Related]
39. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
Ashraf S; Alsharedi M
Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
[TBL] [Abstract][Full Text] [Related]
40. [First report on successful application of nivolumab in Hungary for the treatment of locally recurrent head and neck squamous cell carcinoma].
Bellyei S; Bakó P; Orosz É; Molnár K; Remenár É; Mangel L
Magy Onkol; 2018 Sep; 62(3):175-178. PubMed ID: 30256884
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
